Drug intelligence / Profile preview

RV-P1501

Development stage: Phase 2
Lead developer: Academia Sinica
Modality: Cell Therapies
Administration: Intramuscular

Overview

RV-P1501 is a combination therapy consisting of a medical-grade hyaluronan (hyaluronic acid) scaffold and autologous bone marrow mononuclear cells (BMMNCs). Developed primarily for the treatment of peripheral artery occlusive disease (PAOD) and critical limb ischemia, the hyaluronan component serves as a biocompatible delivery vehicle that enhances the local retention, survival, and pro-angiogenic activity of the transplanted cells. By providing a supportive microenvironment and interacting with cell surface receptors such as CD44, RV-P1501 facilitates therapeutic angiogenesis, aiming to restore blood flow to ischemic limbs and prevent amputation. The program has been evaluated in Phase I/II clinical trials sponsored by Academia Sinica in collaboration with Rovii Biotech.

Other names: hyaluronanhyaluronic acid

Beyond the preview

Go deeper on RV-P1501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV-P1501.

Explore the full profile